GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Glycorex Transplantation AB (NGM:GTAB B) » Definitions » EBIT

Glycorex Transplantation AB (NGM:GTAB B) EBIT : kr-8.56 Mil (TTM As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Glycorex Transplantation AB EBIT?

Glycorex Transplantation AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was kr-1.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-8.56 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Glycorex Transplantation AB's annualized ROC % for the quarter that ended in Mar. 2025 was -13.35%. Glycorex Transplantation AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -42.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Glycorex Transplantation AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -5.25%.


Glycorex Transplantation AB EBIT Historical Data

The historical data trend for Glycorex Transplantation AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glycorex Transplantation AB EBIT Chart

Glycorex Transplantation AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.71 -11.97 -8.27 -17.89 -10.44

Glycorex Transplantation AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.37 -2.02 -3.00 -2.06 -1.49

Competitive Comparison of Glycorex Transplantation AB's EBIT

For the Biotechnology subindustry, Glycorex Transplantation AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's EV-to-EBIT falls into.


;
;

Glycorex Transplantation AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB  (NGM:GTAB B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Glycorex Transplantation AB's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=-5.952 * ( 1 - 0% )/( (45.993 + 43.197)/ 2 )
=-5.952/44.595
=-13.35 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Glycorex Transplantation AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.952/( ( (12.658 + max(1.647, 0)) + (11.287 + max(2.308, 0)) )/ 2 )
=-5.952/( ( 14.305 + 13.595 )/ 2 )
=-5.952/13.95
=-42.67 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.01 + 4.729 + 0) - (0 + 0 + 10.092)
=1.647

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.215 + 5.022 + 0) - (0 + 0 + 9.929)
=2.308

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Glycorex Transplantation AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=-8.562/163.100
=-5.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB EBIT Related Terms

Thank you for viewing the detailed overview of Glycorex Transplantation AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Glycorex Transplantation AB Business Description

Traded in Other Exchanges
Address
Solvegatan 41, Lund, SWE, 223 70
Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.

Glycorex Transplantation AB Headlines

No Headlines